Neumora Therapeutics NMRA Cash Flow Statement (2022-2026)

NASDAQ NMRA
$0.68 -0.01 (-2.05%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Neumora Therapeutics Quarterly Cash Flow Statement

Periods 16 quarters
Latest Jun 2026

Neumora Therapeutics reported cash from operations of -$39.53M and free cash flow of -$39.53M for the quarter ended Jun 2026, up 24.6% year over year. This cash flow statement covers 16 quarters of results from Sep 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -29.20M-30.72M-39.17M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M-43.08M
Share-based Compensation 2.79M2.19M2.54M6.45M6.05M7.37M12.77M9.95M9.90M9.32M7.17M5.98M7.41M7.41M7.18M
Gains from Sales and Divestitures -0.06M0.07M
Asset Writedowns and Impairment 0.22M
Cash from Operations -30.37M-33.04M-31.02M-47.77M-51.44M-42.95M-56.16M-33.48M-50.34M-59.45M-52.40M-46.63M-47.95M-46.40M-39.53M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization 0.15M0.16M0.17M0.17M0.20M0.16M0.16M0.16M0.16M0.16M0.02M0.02M0.01M0.01M0.01M
Change in Working Capital
Change in Account Payables -3.11M-6.01M7.04M0.31M-1.91M1.16M-0.41M5.03M-2.90M-2.25M-0.41M-0.10M2.83M1.68M-0.91M
Change in Accured Expenses 7.03M-0.74M3.12M6.26M-2.16M-4.11M1.94M7.58M1.83M1.68M-6.33M4.87M3.98M-4.02M-1.44M
Other Working Capital Changes 11.25M-7.86M4.24M6.89M8.13M-7.35M9.74M-17.69M-0.60M-0.97M-0.91M0.04M4.60M-1.64M1.51M
Investing Activities
Capital Expenditures 0.02M0.04M0.04M0.04M
Sales of Property, Plant and Equipment 0.08M0.09M0.05M0.07M
Change in Intangibles 0.78M
Cash from Investing Activities -8.03M2.82M24.08M23.82M13.68M-150.00M21.25M156.99M-98.80M44.16M30.40M51.32M42.65M0.07M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Issuances -0.14M38.90M
Change in Capital Stock
Net Equity Issued and Repurchased 24.97M0.60M0.40M231.56M1.84M2.65M1.76M1.23M0.06M0.22M
Misc.
Cash from Financing Activities 26.83M0.10M0.29M232.02M-0.48M1.84M2.65M1.53M15.57M18.46M-0.14M58.77M10.88M9.29M
Change in Cash -11.56M-30.12M-6.65M208.07M-38.25M-191.11M-32.25M125.04M-133.57M-15.29M-3.55M4.55M53.46M-35.46M-30.24M
Free Cash Flow -30.39M-33.08M-31.02M-47.81M-51.49M-42.95M-56.16M-33.48M-50.34M-59.45M-52.40M-46.63M-47.95M-46.40M-39.53M
Net Cash Flow -11.56M-30.12M-6.65M208.07M-38.25M-191.11M-32.25M125.04M-133.57M-15.29M-3.55M4.55M53.46M-35.46M-30.24M

Neumora Therapeutics Cash Flow Statement API

Pull Neumora Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NMRA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY